Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-inject...
What market share potential does Z-1018 have given its tolerability advantage, and how might it impact competitive dynamics in the shingles vaccine space?
What are the expected timelines for Phase 3 enrollment and potential FDA approval compared to Shingrix's pathway?
How will the positive Phase 1/2 data affect Dynavax's valuation and short-term stock momentum?
21 days ago